WO2007078726A2 - Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin - Google Patents

Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin Download PDF

Info

Publication number
WO2007078726A2
WO2007078726A2 PCT/US2006/047380 US2006047380W WO2007078726A2 WO 2007078726 A2 WO2007078726 A2 WO 2007078726A2 US 2006047380 W US2006047380 W US 2006047380W WO 2007078726 A2 WO2007078726 A2 WO 2007078726A2
Authority
WO
WIPO (PCT)
Prior art keywords
weight
pharmaceutical composition
dpp
inhibitor
milligrams
Prior art date
Application number
PCT/US2006/047380
Other languages
French (fr)
Other versions
WO2007078726A3 (en
Inventor
Ashkan Kamali
Laman Alani
Kyle A. Fliszar
Soumojeet Ghosh
Monica Tijerina
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38228726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007078726(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to US12/085,722 priority Critical patent/US8414921B2/en
Priority to EP06839329A priority patent/EP1962827A4/en
Priority to CN2006800471037A priority patent/CN101365432B/en
Priority to JP2008545737A priority patent/JP5165582B2/en
Priority to AU2006333151A priority patent/AU2006333151B2/en
Priority to CA002633167A priority patent/CA2633167A1/en
Publication of WO2007078726A2 publication Critical patent/WO2007078726A2/en
Publication of WO2007078726A3 publication Critical patent/WO2007078726A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • Type 2 diabetes is a chronic and progressive disease arising from a complex pathophysiology involving the dual endocrine defects of insulin resistance and impaired insulin secretion.
  • the treatment of Type 2 diabetes typically begins with diet and exercise, followed by oral antidiabetic monotherapy.
  • these regimens do not sufficiently control glycaemia during long-term treatment, leading to a requirement for combination therapy within several years following diagnosis.
  • co-prescription of two or more oral antidiabetic drugs may result in treatment regimens that are complex and difficult for many patients to follow.
  • Combining two or more oral antidiabetic agents into a single tablet provides a potential means of delivering combination therapy without adding to the complexity of patients' daily regimens.
  • Such formulations have been well accepted in other disease indications, such as hypertension (HYZAARTM which is a combination of losartan potassium and hydrochlorothiazide) and cholesterol lowering (VYTORINTM which is a combination of simvastatin and ezetimibe).
  • hypertension HYZAARTM which is a combination of losartan potassium and hydrochlorothiazide
  • VYTORINTM cholesterol lowering
  • the selection of effective and well -tolerated treatments is a key step in the design of a combination tablet.
  • the components have complementary mechanisms of action and compatible pharmacokinetic profiles.
  • Examples of marketed combination tablets containing two oral antidiabetic agents include GlucovanceTM (metformin and glyburide), AvandametTM (metformin and rosiglitazone), and MetaglipTM (metformin and glipizide).
  • Metformin represents the only oral antidiabetic agent proven to reduce the total burden of microvascular and macrovascular diabetic complications and to prolong the lives of Type 2 diabetic patients. Furthermore, metformin treatment is often associated with reductions in body weight in overweight patients and with improvements in lipid profiles in dyslipidemic patients.
  • DPP-4 inhibitors represent a novel class of agents that are being developed for the treatment or improvement in glycemic control in patients with Type 2 diabetes.
  • Specific DPP-4 inhibitors currently in clinical trials for the treatment of Type 2 diabetes include sitagliptin phosphate (MK-0431), vildagliptin (LAF-237), saxagliptin (BMS-47718), P93/01 (Prosidion), SYR322 (Takeda), GSK 823093, Roche 0730699, TS021 (Taisho), E3024 (Eisai), and PHX-1149 (Phenomix).
  • Sitagliptin phosphate having structural formula I below is the dihydrogenphosphate salt of (2R)-4-oxo ⁇ -[3-(trifluorornethyl)-5,6-dihydro[l ) 2 : ,4]tria2 ⁇ lo[4,3- ⁇ ]pyrazin-7(8H)-yl]-l-(2,4,5- trifluorophenyl)butan ⁇ 2-amine.
  • sitagliptin phosphate is in the form of a crystalline anhydrate or monohydrate. In a class of this embodiment, sitagliptin phosphate is in the form of a crystalline monohydrate.
  • Sitagliptin free base and pharmaceutically acceptable salts thereof are disclosed in U.S. Patent No. 6,699,871, the contents of which are hereby incorporated by reference in their entirety.
  • Crystalline sitagliptin phosphate monohydrate is disclosed in international patent publication WO 2005/0031335 published on January 13, 2005.
  • sitagliptin phosphate (MK-0431) including its synthesis and pharmacological properties, reference is made to the following publications: (1) CF. Deacon, "MK-431,” Curr. Opin. Invest. Drugs. 6: 419-426 (2005) and (2) "MK-0431", Drugs of the Future.” 30: 337-343 (2005).
  • Vildagliptin (LAF-237) is the generic name for (S)- 1 -[(3 -hydroxy- 1- adamantyl)ammo]acetyl-2-cyano-pyrrolidine having structural formula II.
  • Vildagliptin is specifically disclosed in US Patent No. 6,166,063, the contents of which are hereby incorporated by reference in their entirety.
  • Saxagliptin (BMS-47718) is a methanoprolinenitrile of structural formula III below. Saxagliptm is specifically disclosed in US Patent No. 6,395,767, the contents of which are hereby incorporated by reference in their entirety.
  • the present invention provides for pharmaceutical compositions of a fixed-dose combination of a DPP -4 inhibitor and metformin which are prepared by dry or wet processing methods.
  • the pharmaceutical compositions of the present invention provide for immediate release of the two active pharmaceutical ingredients.
  • the pharmaceutical compositions of the present invention are in the dosage form of a tablet, and, in particular, a film-coated tablet.
  • the present invention also provides a process to prepare pharmaceutical compositions of a fixed-dose combination of a DPP -4 inhibitor and metformin by dry or wet processing methods.
  • the dry processing methods include dry compression and dry granulation, and the wet processing methods include wet granulation.
  • Another aspect of the present invention provides methods for the treatment of Type 2 diabetes by administering to a host in need of such treatment a therapeutically effective amount of a pharmaceutical composition of the present invention.
  • the present invention is directed to novel pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor and metformin, or pharmaceutically acceptable salts of each thereof, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.
  • the invention is directed to pharmaceutical compositions comprising fixed-dose combinations of sitagliptin phosphate and metformin hydrochloride.
  • One aspect of the present invention is directed to dosage forms for the medicinal administration of a fixed-dose combination of a DPP-4 inhibitor and metformin.
  • dosage forms may be in the powder or solid format and include tablets, capsules, sachets, etc.
  • a particular solid dosage form relates to tablets comprising a fixed-dose combination of a DPP-4 inhibitor and metformin hydrochloride (1,1 -dimethylbiguanide hydrochloride) .
  • the pharmaceutical compositions comprise
  • the pharmaceutical compositions may also contain one or more excipients which excipients are selected from the group consisting of one or more binding agents (binders); one or more diluents; one or more surfactants or wetting agents; one or more disintegrants; and one or more antioxidants.
  • the DPP-4 inhibitor is selected from the group consisting of sitagliptin, vildagliptin, saxagliptin, P93/01, SYR322, GSK 823093, Roche 0730699, TS021, E3024, and PHX-1149.
  • the DPP-4 inhibitor is sitagliptin, vildagliptin, or saxagliptin.
  • the DPP-4 inhibitor is sitagliptin.
  • a preferred pharmaceutically acceptable salt of sitagliptin is the dihydrogenphophate salt of structural formula I above (sitagliptin phosphate).
  • a preferred form of the dihydrogenphosphate salt is the crystalline monohydrate disclosed in WO 2005/0031335.
  • sitagliptin and pharmaceutically acceptable salts thereof is disclosed in US Patent No. 6,699,871, the contents of which are herein incorporated by reference in their entirety.
  • the preparation of sitagliptin phosphate monohydrate is disclosed in international patent publication WO 2005/0031335 published on January 13, 2005, the contents of which are herein incorporated by reference in their entirety.
  • the dosage strength of the DPP-4 inhibitor for incorporation into the pharmaceutical compositions of the present invention is an amount from about 1 milligram to about 250 milligrams of the active moiety.
  • a preferred dosage strength of the DPP-4 inhibitor is an amount from about 25 milligrams to about 200 milligrams of the active moiety.
  • Discrete dosage strengths are the equivalent of 25, 50, 75, 100, 150, and 200 milligrams of the DPP-4 inhibitor active moiety.
  • active moiety is meant the free base form of the DPP-4 inhibitor as an anhydrate.
  • the unit dosage strength of sitagliptin free base anhydrate (active moiety) for inclusion into the fixed-dose combination pharmaceutical compositions of the present invention is 25, 50, 75, 100, 150, or 200 milligrams.
  • a preferred dosage strength of sitagliptin is 50 or 100 milligrams.
  • An equivalent amount of sitagliptin phosphate monohydrate to the sitagliptin free base anhydrate is used in the pharmaceutical compositions, namely, 32.13, 64.25, 96.38, 128.5, 192.75, and 257 milligrams, respectively.
  • the unit dosage strength of the metformin hydrochloride for incorporation into the fixed- dose combination of the present invention is 250, 500, 625, 750, 850, and 1000 milligrams. These unit dosage strengths of metformin hydrochloride represent the dosage strengths approved in the U.S. for marketing to treat Type 2 diabetes.
  • sitagliptin (equivalent to 64.25 milligrams of sitagliptin phosphate monohydrate) and 500 milligrams metformin hydrochloride;
  • sitagliptin (equivalent to 64.25 milligrams of sitagliptin phosphate monohydrate) and 850 milligrams metformin hydrochloride; (3) 50 milligrams of sitagliptin (equivalent to 64.25 milligrams of sitagliptin phosphate monohydrate) and 1000 milligrams metformin hydrochloride; (4) 100 milligrams of sitagliptin (equivalent to 128.5 milligrams of sitagliptin phosphate monohydrate) and 500 milligrams metformin hydrochloride;
  • sitagliptin 100 milligrams of sitagliptin (equivalent to 128.5 milligrams of sitagliptin phosphate monohydrate) and 850 milligrams metformin hydrochloride; and (6) 100 milligrams of sitagliptin (equivalent to 128.5 milligrams of sitagliptin phosphate monohydrate) and 1000 milligrams metformin hydrochloride.
  • compositions of the present invention are prepared by wet or dry processing methods.
  • the pharmaceutical compositions are prepared by wet processing methods.
  • the pharmaceutical compositions are prepared by wet granulation methods. With wet granulation either high-shear granulation or fluid-bed granulation may be used. In one embodiment fluid-bed granulation is employed which has the advantage of affording tablets with higher diametric strength.
  • the pharmaceutical compositions are prepared by dry processing methods.
  • the pharmaceutical compositions are prepared by direct compression or dry granulation methods.
  • An embodiment of dry granulation is roller compaction.
  • compositions obtained by the dry or wet processing methods may be compressed into tablets, encapsulated, or metered into sachets.
  • the pharmaceutical compositions contain one or more lubricants or glidants.
  • lubricants include magnesium stearate, calcium stearate, stearic acid, sodium stearyl fumarate, hydrogenated castor oil, and mixtures thereof.
  • a preferred lubricant is magnesium stearate or sodium stearyl fumarate or a mixture thereof.
  • glidants include colloidal silicon dioxide, calcium phosphate tribasic, magnesium silicate, and talc.
  • the pharmaceutical compositions of the present invention optionally contain one or more binding agents.
  • binding agents include hydroxypropylcellulose (HPC), hydroxypropylmethyl cellulose (HMPC), hydroxyethyl cellulose, starch 1500, polyvinylpyrrolidone (povidone), and co-povidone.
  • a preferred binding agent is polyvinylpyrrolidone.
  • compositions of the present invention may also optionally contain one or more diluents.
  • diluents include mannitol, sorbitol, dibasic calcium phosphate dihydrate, microcrystalline cellulose, and powdered cellulose.
  • a preferred diluent is microcrystalline cellulose.
  • Microcrystalline cellulose is available from several suppliers and includes Avicel PH 101, Avicel PH 102, Avicel, PH 103, Avicel PH 105, and Avicel PH 200, manufactured by the FMC Corporation.
  • the pharmaceutical compositions of the present invention may also optionally contain a disintegrant.
  • the disintegrant may be one of several modified starches, modified cellulose polymers, or polycarboxylic acids, such as croscarmellose sodium, sodium starch glycollate, polacrillin potassium, and carboxymethylcellulose calcium (CMC Calcium).
  • the disintegrant is croscarmellose sodium.
  • Croscarmellose sodium NF Type A is commercially available under the trade name "Ac-di-sol.”
  • the pharmaceutical compositions of the present invention may also optionally contain one or more surfactants or wetting agents.
  • the surfactant may be anionic, cationic, or neutral.
  • Anionic surfactants include sodium lauryl sulfate, sodium dodecanesulfonate, sodium oleyl sulfate, and sodium laurate mixed with stearates and talc.
  • Cationic surfactants include benzalkonium chlorides and alkyltrimethylammonium bromides.
  • Neutral surfactants include glyceryl monooleate, polyoxyethylene sorbitan fatty acid esters, polyvinyl alcohol, and sorbitan esters.
  • Embodiments of wetting agents include poloxamer, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, and polyoxyethylene stearates.
  • An anti-oxidant may optionally be added to the formulation to impart chemical stability.
  • the anti-oxidant is selected from the group consisting of ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocopherol, extracts of natural origin rich in tocopherol, L-ascorbic acid and its sodium or calcium salts, ascorbyl palmitate, propyl gallate, oc ⁇ yl gallate, dodecyl gallate, butylated hydroxytoluene (BHT), and butylated hydroxyanisole (BHA).
  • the antioxidant is BHT or BHA.
  • Preferred dosage forms for the pharmaceutical compositions of the present invention are tablets which are prepared by compression methods.
  • Such tablets may be film-coated such as with a mixture of hydroxypropylcellulose and hydroxypropylmethylcellulose containing titanium dioxide and/or other coloring agents, such as iron oxides, dyes, and lakes; a mixture of polyvinyl alcohol (PVA) and polyethylene glycol (PEG) containing titanium dioxide and/or other coloring agents, such as iron oxides, dyes, and lakes; or any other suitable immediate-release film-coating agent(s).
  • PVA polyvinyl alcohol
  • PEG polyethylene glycol
  • the coat provides taste masking and additional stability to the final tablet.
  • a commercial film-coat is Opadry® which is a formulated powder blend provided by Colorcon.
  • the pharmaceutical compositions contain about 3 to 20 % by weight of a DPP-4 inhibitor as one of the two pharmaceutically active ingredients; about 25 to 94 % by weight of metformin hydrochloride as the second pharmaceutically active ingredient; about 0 to 35 % by weight of a binding agent; and about 0.1 to 10 % by weight of a lubricant.
  • the binding agent is polyvinylpyrrolidone or hydroxypropylcellulose
  • the lubricant is magnesium stearate or sodium stearyl fumarate.
  • the binding agent is polyvinylpyrrolidone
  • the lubricant is sodium stearyl fumarate.
  • the pharmaceutical compositions optionally contain about 0 to 3 % by weight of a surfactant and/or about 0 to 70 %.by weight of a diluent.
  • the surfactant is sodium lauryl sulfate and the diluent is microcrystalline cellulose.
  • the pharmaceutical compositions of the present invention are prepared by wet granulation methods and comprise about 5 to 18 % by weight of a DPP-4 inhibitor as one of the two pharmaceutically active ingredients; about 65 to 77 % by weight of metformin hydrochloride as the second pharmaceutically active ingredient; about 4 to 9 % by weight of a binding agent; and about 1 to 2 % by weight of a lubricant.
  • the binding agent is polyvinylpyrrolidone or hydroxypropylcellulose
  • the lubricant is magnesium stearate or sodium stearyl fumarate.
  • the binding agent is polyvinylpyrrolidone.
  • the pharmaceutical compositions optionally contain about 0.5 to 1 % to by weight of a surfactant and/or about 5 to 15 % by weight of a diluent.
  • the surfactant is sodium lauryl sulfate and the diluent is microcrystalline cellulose.
  • compositions as envisioned for commercial development are as follows: Tablets of 50 mg DPP-4 inhibitor/500 mg metformin HCl potency:
  • DPP-4 inhibitor about 9 % by weight of the DPP-4 inhibitor; about 73 % by weight of metformin hydrochloride; about 7 % by weight of a binding agent; about 1 to 2 % by weight of a lubricant; and optionally about 10 % by weight of a diluent and/or about 0.5 % by weight of a surfactant.
  • the DPP-4 inhibitor is sitagliptin, vildagliptin, or saxagliptin;
  • the binding agent is polyvinylpyrrolidone
  • the lubricant is magnesium stearate or sodium stearyl fumarate
  • the diluent is microcrystalline cellulose
  • the surfactant is sodium lauryl sulfate.
  • the DPP-4 inhibitor is sitagliptin.
  • DPP-4 inhibitor about 6 % by weight of the DPP-4 inhibitor; about 76 % by weight of metformin hydrochloride; about 7 % by weight of a binding agent; about 1 to 2 % by weight of a lubricant; and optionally about 10 % by weight of a diluent and/or about 0.5 % by weight of a surfactant.
  • the DPP-4 inhibitor is sitagliptin, vildagliptin, or saxagliptin;
  • the binding agent is polyvinylpyrrolidone
  • the lubricant is magnesium stearate or sodium stearyl fumarate
  • the diluent is microcrystalline cellulose
  • the surfactant is sodium lauryl sulfate.
  • the DPP-4 inhibitor is sitagliptin.
  • DPP-4 inhibitor about 5 % by weight of the DPP-4 inhibitor; about 77 % by weight of metformin hydrochloride; about 7 % by weight of a binding agent; about 1 to 2 % by weight of a lubricant; and . optionally about 10 % by weight of a diluent and/or about 0.5 % by weight of a surfactant.
  • the DPP-4 inhibitor is sitagliptin, vildagliptin, or saxagliptin;
  • the binding agent is polyvinylpyrrolidone
  • the lubricant is magnesium stearate or sodium stearyl fumarate
  • the diluent is microcrystalline cellulose
  • the surfactant is sodium lauryl sulfate.
  • the DPP-4 inhibitor is sitagliptin. .
  • the DPP-4 inhibitor is sitagliptin, vildagiiptin, or saxagliptin; the binding agent is polyvinylpyrrolidone, the lubricant is magnesium stearate or sodium stearyl fumarate, the diluent is microcrystalline cellulose, and the surfactant is sodium lauryl sulfate.
  • the DPP-4 inhibitor is sitagliptin.
  • the DPP-4 inhibitor is sitagliptin, vildagiiptin, or saxagliptin; the binding agent is polyvinylpyrrolidone, the lubricant is magnesium stearate or sodium stearyl fumarate, the diluent is microcrystalline cellulose, and the surfactant is sodium lauryl sulfate.
  • the DPP-4 inhibitor is sitagliptin.
  • DPP-4 inhibitor about 10 % by weight of the DPP-4 inhibitor; about 77 % by weight of metformin hydrochloride; about 7 % by weight of a binding agent; about 1 to 2 % by weight of a lubricant; and optionally about 4 % by weight of a diluent and/or about 0.5 % by weight of a surfactant.
  • the DPP-4 inhibitor is sitagliptin, vildagiiptin, or saxagliptin;
  • the binding agent is polyvinylpyrrolidone
  • the lubricant is magnesium stearate or sodium stearyl fumarate
  • the diluent is microcrystalline cellulose
  • the surfactant is sodium lauryl sulfate.
  • the DPP-4 inhibitor is sitagliptin.
  • the pharmaceutical tablet compositions of the present invention may also contain one or more additional formulation ingredients selected from a wide variety of excipients known in the pharmaceutical formulation art. According to the desired properties of the pharmaceutical composition, any number of ingredients may be selected, alone or in combination, based upon their known uses in preparing tablet compositions. Such ingredients include, but are not limited to, diluents, compression aids, glidants, disintegrants, lubricants, flavors, flavor enhancers, sweeteners, and preservatives.
  • tablette as used herein is intended to encompass compressed pharmaceutical dosage formulations of all shapes and sizes, whether coated or uncoated. Substances which may be used for coating include hydroxypropylcellulose, hydroxypropylmethylcellulose, titanium dioxide, talc, sweeteners, colorants, and flavoring agents.
  • the pharmaceutical compositions of the present invention are prepared by wet granulation (high shear and/or fluid bed). Granulation is a process in which binding agent is added either through the granulating solution or through addition to the granulating bowl to form granules. The steps involved in the wet granulation method comprise the following:
  • step 1 (1) the active pharmaceutical ingredients metformin hydrochloride and the DPP-4 inhibitor are added to the granulating bowl; (2) optional disintegrants are added to step 1 ;
  • the binding agent such as polyvinylpyrrolidone or hydroxypropylcellulose
  • a surfactant such as sodium lauryl sulfate
  • granules prepared by high shear granulation are tray-dried in an oven or dried in a fluid bed dryer.
  • granules prepared by fluid bed granulation granules are dried in a fluid bed dryer;
  • dried granules are resized in suitable mill; (6) optional diluents (such as microcrystalline cellulose and dibasic calcium phosphate dihydrate) are blended with dried granules in a suitable blender;
  • lubricants or glidants are added to the blend from step 6 in a suitable blender; .
  • lubricated granule mixture from step 7 may be filled into bottles, sachets, or capsules or compressed into desired tablet image; . . . . , .
  • the resulting tablets may be film-coated.
  • the steps involved in the dry processing (direct compression or dry granulation) methods comprise:
  • step 1 (2) optional disintegrants are added to step 1 ;
  • step 2 (3) optional binders and/or diluents are added to step 2;
  • step 3 (4) lubricants or glidants are added to step 3;
  • mixture from step 4 may be filled into bottles, sachets, or capsules or compressed into desired tablet image, or processed through a roller compactor;
  • granules may be resized in a suitable mill, if necessary;
  • optional diluents may be added to the resulting granules, in a suitable blender to improve compaction properties; . .
  • lubricated granule mixture from step 8 may be filled into bottles, sachets, or capsules or compressed into desired tablet image;
  • the resulting tablets from step 5 or step 9 may be film-coated.
  • the present invention also provides methods for treating Type 2 diabetes by orally administering to a host in need of such treatment a therapeutically effective amount of one of the fixed- dose combination pharmaceutical compositions of the present invention.
  • the host in need of such treatment is a human.
  • the pharmaceutical composition is in the dosage form of a tablet.
  • the pharmaceutical compositions comprising the fixed-dose combination may be administered once-daily (QD), twice-daily (BID), or thrice-daily (TID).
  • Sitagliptin phosphate monohydrate and metformin hydrochloride were loaded into a high shear granulator or a fluid bed granulator.
  • high shear granulation purified water containing sodium lauryl sulfate was added to the APIs, in addition to the polyvinylpyrrolidone binding agent over a period of 3-5 minutes.
  • the wetted mass was either tray dried at 40 0 C or dried in a fluid-bed dryer at an inlet temperature of 45-60 0 C for 3-6 minutes.
  • purified water containing polyvinylpyrrolidone and sodium lauryl sulfate was added to APIs over a period of 30- 60 minutes.
  • the wetted mass was dried in a fluid-bed dryer at an inlet temperature of 45-60 0 C.
  • the dried material was then milled using a co-mill to achieve fine granules.
  • microcrystalline cellulose was added to the granules and blended in a twin shell-blender for 200 revolutions.
  • the lubricant sodium stearyl fumarate
  • the lubricated mixture was compressed using a rotary tablet press to provide a 689 mg uncoated tablet.
  • the tablets were optionally coated with Opadry ® II suspension (polyvinyl alcohol, polyethylene glycol, titanium dioxide, and talc, with or without colorants) to an approximate 2.5% weight gain to provide a 706 mg coated tablet.
  • Tablets were prepared by wet-granulation using essentially the procedure of Example 1 to provide a 1117 mg uncoated tablet.
  • the tablets were optionally coated with 27.9 mg of a standard Opadry II film-coat formula to provide a 1145 mg coated tablet.
  • Tablets were prepared by wet-granulation using essentially the procedure of Example 1 to provide a 1300 mg uncoated tablet.
  • the tablets were optionally coated with an Opadry ® ⁇ suspension (polyvinyl alcohol, polyethylene glycol, titanium dioxide, and talc, with or without colorants) to an approximate 2.5% weight gain to provide a 1333 mg coated tablet.
  • Opadry ® ⁇ suspension polyvinyl alcohol, polyethylene glycol, titanium dioxide, and talc, with or without colorants
  • Sitagliptin phosphate monohydrate and metformin hydrochloride were loaded into a high shear granulator or a fluid bed granulator.
  • high shear granulation purified water was added to the APIs, in addition to the polyvinylpyrrolidone binding agent over a period of 3-5 minutes.
  • the wetted mass was either tray dried at 40 0 C or dried in a fluid-bed dryer at an inlet temperature of 45- 60 0 C for 3-6 minutes.
  • purified water containing polyvinylpyrrolidone was added to APIs over a period of 30-60 minutes. The wetted mass was dried in a fluid-bed dryer at an inlet temperature of 45-60 0 C.
  • the dried material was then milled using a co-mill to achieve fine granules. After milling, microcrystalline cellulose was added to the granules and blended in a twin shell-blender for 200 revolutions.
  • the lubricant magnesium stearate
  • the lubricated mixture was compressed using a rotary tablet press to provide a 689 mg uncoated tablet.
  • the tablet was then optionally film-coated with an Opadry ® II suspension (polyvinyl alcohol, polyethylene glycol, titanium dioxide, and talc, with or without colorants) to an approximate 2.5% weight gain to provide a 706 mg coated tablet.
  • Sitagliptin phosphate monohydrate and metformin hydrochloride were loaded into a high shear granulator or a fluid bed granulator.
  • high shear granulation purified water containing sodium lauryl sulfate was added to the APIs, in addition to the polyvinylpyrrolidone binding agent over a period of 3-5 minutes.
  • the wetted mass was either tray dried at 40 0 C or dried in a fluid-bed dryer at an inlet temperature of 45-60 "C for 3-6 minutes.
  • purified water containing polyvinylpyrrolidone and sodium lauryl sulfate was added to APIs over a period of 30- 60 minutes.
  • the wetted mass was dried in a fluid-bed dryer at an inlet temperature of 45-60 0 C.
  • the dried material was then milled using a co-mill to achieve fine granules.
  • microcrystalline cellulose was added to the granules and blended in a twin shell-blender for 200 revolutions.
  • the lubricant (magnesium stearate) was then added and blended an additional 100 revolutions.
  • the lubricated mixture was compressed using a rotary tablet press to provide a 1300 mg uncoated tablet.
  • the tablet was then optionally film-coated with an Opadry ® II suspension (polyvinyl alcohol, polyethylene glycol, titanium dioxide, and talc, with or without colorants) to an approximate 2.5% weight gain to provide a 1333 mg coated tablet.
  • Opadry ® II suspension polyvinyl alcohol, polyethylene glycol, titanium dioxide, and talc, with or without colorants
  • Example 1 to provide a 1300 mg uncoated tablet.
  • Tablets were prepared by fluid-bed granulation using essentially the procedure of Example 1 to provide a 768 mg uncoated tablet.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed are pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and metformin, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.

Description

TITLE OF THE INVENTION
PHARMACEUTICAL COMPOSITIONS OF COMBINATIONS OF DIPEPTIDYL PEPTEDASE-4
INHIBITORS WITH METFORMIN
BACKGROUND OF THE INVENTION
Type 2 diabetes is a chronic and progressive disease arising from a complex pathophysiology involving the dual endocrine defects of insulin resistance and impaired insulin secretion. The treatment of Type 2 diabetes typically begins with diet and exercise, followed by oral antidiabetic monotherapy. For many patients, these regimens do not sufficiently control glycaemia during long-term treatment, leading to a requirement for combination therapy within several years following diagnosis. However, co-prescription of two or more oral antidiabetic drugs may result in treatment regimens that are complex and difficult for many patients to follow. Combining two or more oral antidiabetic agents into a single tablet provides a potential means of delivering combination therapy without adding to the complexity of patients' daily regimens. Such formulations have been well accepted in other disease indications, such as hypertension (HYZAAR™ which is a combination of losartan potassium and hydrochlorothiazide) and cholesterol lowering (VYTORIN™ which is a combination of simvastatin and ezetimibe). The selection of effective and well -tolerated treatments is a key step in the design of a combination tablet. Moreover, it is essential that the components have complementary mechanisms of action and compatible pharmacokinetic profiles. Examples of marketed combination tablets containing two oral antidiabetic agents include Glucovance™ (metformin and glyburide), Avandamet™ (metformin and rosiglitazone), and Metaglip™ (metformin and glipizide).
Metformin represents the only oral antidiabetic agent proven to reduce the total burden of microvascular and macrovascular diabetic complications and to prolong the lives of Type 2 diabetic patients. Furthermore, metformin treatment is often associated with reductions in body weight in overweight patients and with improvements in lipid profiles in dyslipidemic patients.
Dipeptidyl peρtidase-4 (DPP-4) inhibitors represent a novel class of agents that are being developed for the treatment or improvement in glycemic control in patients with Type 2 diabetes. Specific DPP-4 inhibitors currently in clinical trials for the treatment of Type 2 diabetes include sitagliptin phosphate (MK-0431), vildagliptin (LAF-237), saxagliptin (BMS-47718), P93/01 (Prosidion), SYR322 (Takeda), GSK 823093, Roche 0730699, TS021 (Taisho), E3024 (Eisai), and PHX-1149 (Phenomix). For example, oral administration of vildagliptin or sitagliptin to human Type 2 diabetics has been found to reduce fasting glucose and postprandial glucose excursion in association with significantly reduced HbAi c levels. For reviews on the application of DPP-4 inhibitors for the treatment of Type 2 diabetes, reference is made to the following publications: (1) H.-U. Demuth, et al., "Type 2 diabetes — Therapy with dipeptidyl peptidase IV inhibitors, Biochim. Biophvs. Acta. 1751: 33-44 (2005) and (2) K. Augustyns, et al., "Inhibitors of proline-specific dipeptidyl peptidases: DPP IV inhibitors as a novel approach for the treatment of Type 2 diabetes," Expert Opin. Ther. Patents, 15: 1387-1407 (2005). Sitagliptin phosphate having structural formula I below is the dihydrogenphosphate salt of (2R)-4-oxo^-[3-(trifluorornethyl)-5,6-dihydro[l)2:,4]tria2θlo[4,3-α]pyrazin-7(8H)-yl]-l-(2,4,5- trifluorophenyl)butan~2-amine.
Figure imgf000003_0001
In one embodiment sitagliptin phosphate is in the form of a crystalline anhydrate or monohydrate. In a class of this embodiment, sitagliptin phosphate is in the form of a crystalline monohydrate. Sitagliptin free base and pharmaceutically acceptable salts thereof are disclosed in U.S. Patent No. 6,699,871, the contents of which are hereby incorporated by reference in their entirety. Crystalline sitagliptin phosphate monohydrate is disclosed in international patent publication WO 2005/0031335 published on January 13, 2005. For a review on sitagliptin phosphate (MK-0431) including its synthesis and pharmacological properties, reference is made to the following publications: (1) CF. Deacon, "MK-431," Curr. Opin. Invest. Drugs. 6: 419-426 (2005) and (2) "MK-0431", Drugs of the Future." 30: 337-343 (2005).
Vildagliptin (LAF-237) is the generic name for (S)- 1 -[(3 -hydroxy- 1- adamantyl)ammo]acetyl-2-cyano-pyrrolidine having structural formula II. Vildagliptin is specifically disclosed in US Patent No. 6,166,063, the contents of which are hereby incorporated by reference in their entirety.
Figure imgf000003_0002
Saxagliptin (BMS-47718) is a methanoprolinenitrile of structural formula III below. Saxagliptm is specifically disclosed in US Patent No. 6,395,767, the contents of which are hereby incorporated by reference in their entirety.
Figure imgf000003_0003
The present invention provides for pharmaceutical compositions of a fixed-dose combination of a DPP -4 inhibitor and metformin which are prepared by dry or wet processing methods. The pharmaceutical compositions of the present invention provide for immediate release of the two active pharmaceutical ingredients. In one embodiment the pharmaceutical compositions of the present invention are in the dosage form of a tablet, and, in particular, a film-coated tablet.
The present invention also provides a process to prepare pharmaceutical compositions of a fixed-dose combination of a DPP -4 inhibitor and metformin by dry or wet processing methods. The dry processing methods include dry compression and dry granulation, and the wet processing methods include wet granulation. Another aspect of the present invention provides methods for the treatment of Type 2 diabetes by administering to a host in need of such treatment a therapeutically effective amount of a pharmaceutical composition of the present invention.
These and other aspects will become readily apparent from the detailed description which follows.
SUMMARY OF THE INVENTION
The present invention is directed to novel pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor and metformin, or pharmaceutically acceptable salts of each thereof, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions. In particular, the invention is directed to pharmaceutical compositions comprising fixed-dose combinations of sitagliptin phosphate and metformin hydrochloride.
DETAILED DESCRIPTION OF THE INVENTION One aspect of the present invention is directed to dosage forms for the medicinal administration of a fixed-dose combination of a DPP-4 inhibitor and metformin. Such dosage forms may be in the powder or solid format and include tablets, capsules, sachets, etc. A particular solid dosage form relates to tablets comprising a fixed-dose combination of a DPP-4 inhibitor and metformin hydrochloride (1,1 -dimethylbiguanide hydrochloride) . In a particular aspect of the present invention, the pharmaceutical compositions comprise
(1) a DPP-4 inhibitor, or a pharmaceutically acceptable salt thereof, as one of the two active pharmaceutical ingredients; (2) metformin hydrochloride as the second active pharmaceutical ingredient; and (3) a lubricant or glidant. In an embodiment of this aspect of the present invention, the pharmaceutical compositions may also contain one or more excipients which excipients are selected from the group consisting of one or more binding agents (binders); one or more diluents; one or more surfactants or wetting agents; one or more disintegrants; and one or more antioxidants. In another embodiment of this aspect of the invention, the DPP-4 inhibitor is selected from the group consisting of sitagliptin, vildagliptin, saxagliptin, P93/01, SYR322, GSK 823093, Roche 0730699, TS021, E3024, and PHX-1149. In a class of this embodiment the DPP-4 inhibitor is sitagliptin, vildagliptin, or saxagliptin. In a subclass of this class, the DPP-4 inhibitor is sitagliptin. A preferred pharmaceutically acceptable salt of sitagliptin is the dihydrogenphophate salt of structural formula I above (sitagliptin phosphate). A preferred form of the dihydrogenphosphate salt is the crystalline monohydrate disclosed in WO 2005/0031335.
The preparation of sitagliptin and pharmaceutically acceptable salts thereof is disclosed in US Patent No. 6,699,871, the contents of which are herein incorporated by reference in their entirety. The preparation of sitagliptin phosphate monohydrate is disclosed in international patent publication WO 2005/0031335 published on January 13, 2005, the contents of which are herein incorporated by reference in their entirety.
The dosage strength of the DPP-4 inhibitor for incorporation into the pharmaceutical compositions of the present invention is an amount from about 1 milligram to about 250 milligrams of the active moiety. A preferred dosage strength of the DPP-4 inhibitor is an amount from about 25 milligrams to about 200 milligrams of the active moiety. Discrete dosage strengths are the equivalent of 25, 50, 75, 100, 150, and 200 milligrams of the DPP-4 inhibitor active moiety. By "active moiety" is meant the free base form of the DPP-4 inhibitor as an anhydrate.
The unit dosage strength of sitagliptin free base anhydrate (active moiety) for inclusion into the fixed-dose combination pharmaceutical compositions of the present invention is 25, 50, 75, 100, 150, or 200 milligrams. A preferred dosage strength of sitagliptin is 50 or 100 milligrams. An equivalent amount of sitagliptin phosphate monohydrate to the sitagliptin free base anhydrate is used in the pharmaceutical compositions, namely, 32.13, 64.25, 96.38, 128.5, 192.75, and 257 milligrams, respectively. The unit dosage strength of the metformin hydrochloride for incorporation into the fixed- dose combination of the present invention is 250, 500, 625, 750, 850, and 1000 milligrams. These unit dosage strengths of metformin hydrochloride represent the dosage strengths approved in the U.S. for marketing to treat Type 2 diabetes.
Specific embodiments of dosage strengths for sitagliptin and metformin hydrochloride in the fixed-dose combinations of the present invention are the following:
(1) 50 milligrams of sitagliptin (equivalent to 64.25 milligrams of sitagliptin phosphate monohydrate) and 500 milligrams metformin hydrochloride;
(2) 50 milligrams of sitagliptin (equivalent to 64.25 milligrams of sitagliptin phosphate monohydrate) and 850 milligrams metformin hydrochloride; (3) 50 milligrams of sitagliptin (equivalent to 64.25 milligrams of sitagliptin phosphate monohydrate) and 1000 milligrams metformin hydrochloride; (4) 100 milligrams of sitagliptin (equivalent to 128.5 milligrams of sitagliptin phosphate monohydrate) and 500 milligrams metformin hydrochloride;
(5) 100 milligrams of sitagliptin (equivalent to 128.5 milligrams of sitagliptin phosphate monohydrate) and 850 milligrams metformin hydrochloride; and (6) 100 milligrams of sitagliptin (equivalent to 128.5 milligrams of sitagliptin phosphate monohydrate) and 1000 milligrams metformin hydrochloride.
The pharmaceutical compositions of the present invention are prepared by wet or dry processing methods. In one embodiment the pharmaceutical compositions are prepared by wet processing methods. In a class of this embodiment the pharmaceutical compositions are prepared by wet granulation methods. With wet granulation either high-shear granulation or fluid-bed granulation may be used. In one embodiment fluid-bed granulation is employed which has the advantage of affording tablets with higher diametric strength.
In a second embodiment the pharmaceutical compositions are prepared by dry processing methods. In a class of this embodiment the pharmaceutical compositions are prepared by direct compression or dry granulation methods. An embodiment of dry granulation is roller compaction.
The pharmaceutical compositions obtained by the dry or wet processing methods may be compressed into tablets, encapsulated, or metered into sachets.
The pharmaceutical compositions contain one or more lubricants or glidants. Examples of lubricants include magnesium stearate, calcium stearate, stearic acid, sodium stearyl fumarate, hydrogenated castor oil, and mixtures thereof. A preferred lubricant is magnesium stearate or sodium stearyl fumarate or a mixture thereof. Examples of glidants include colloidal silicon dioxide, calcium phosphate tribasic, magnesium silicate, and talc.
The pharmaceutical compositions of the present invention optionally contain one or more binding agents. Embodiments of binding agents include hydroxypropylcellulose (HPC), hydroxypropylmethyl cellulose (HMPC), hydroxyethyl cellulose, starch 1500, polyvinylpyrrolidone (povidone), and co-povidone. A preferred binding agent is polyvinylpyrrolidone.
The pharmaceutical compositions of the present invention may also optionally contain one or more diluents. Examples of diluents include mannitol, sorbitol, dibasic calcium phosphate dihydrate, microcrystalline cellulose, and powdered cellulose. A preferred diluent is microcrystalline cellulose. Microcrystalline cellulose is available from several suppliers and includes Avicel PH 101, Avicel PH 102, Avicel, PH 103, Avicel PH 105, and Avicel PH 200, manufactured by the FMC Corporation.
The pharmaceutical compositions of the present invention may also optionally contain a disintegrant. The disintegrant may be one of several modified starches, modified cellulose polymers, or polycarboxylic acids, such as croscarmellose sodium, sodium starch glycollate, polacrillin potassium, and carboxymethylcellulose calcium (CMC Calcium). In one embodiment, the disintegrant is croscarmellose sodium. Croscarmellose sodium NF Type A is commercially available under the trade name "Ac-di-sol." The pharmaceutical compositions of the present invention may also optionally contain one or more surfactants or wetting agents. The surfactant may be anionic, cationic, or neutral. Anionic surfactants include sodium lauryl sulfate, sodium dodecanesulfonate, sodium oleyl sulfate, and sodium laurate mixed with stearates and talc. Cationic surfactants include benzalkonium chlorides and alkyltrimethylammonium bromides. Neutral surfactants include glyceryl monooleate, polyoxyethylene sorbitan fatty acid esters, polyvinyl alcohol, and sorbitan esters. Embodiments of wetting agents include poloxamer, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, and polyoxyethylene stearates.
An anti-oxidant may optionally be added to the formulation to impart chemical stability. The anti-oxidant is selected from the group consisting of α-tocopherol, γ-tocopherol, δ-tocopherol, extracts of natural origin rich in tocopherol, L-ascorbic acid and its sodium or calcium salts, ascorbyl palmitate, propyl gallate, ocτyl gallate, dodecyl gallate, butylated hydroxytoluene (BHT), and butylated hydroxyanisole (BHA). In one embodiment, the antioxidant is BHT or BHA.
Preferred dosage forms for the pharmaceutical compositions of the present invention are tablets which are prepared by compression methods. Such tablets may be film-coated such as with a mixture of hydroxypropylcellulose and hydroxypropylmethylcellulose containing titanium dioxide and/or other coloring agents, such as iron oxides, dyes, and lakes; a mixture of polyvinyl alcohol (PVA) and polyethylene glycol (PEG) containing titanium dioxide and/or other coloring agents, such as iron oxides, dyes, and lakes; or any other suitable immediate-release film-coating agent(s). The coat provides taste masking and additional stability to the final tablet. A commercial film-coat is Opadry® which is a formulated powder blend provided by Colorcon.
Finally, a sweetening agent and/or flavoring agent may be added if desired. In one embodiment of the present invention, the pharmaceutical compositions contain about 3 to 20 % by weight of a DPP-4 inhibitor as one of the two pharmaceutically active ingredients; about 25 to 94 % by weight of metformin hydrochloride as the second pharmaceutically active ingredient; about 0 to 35 % by weight of a binding agent; and about 0.1 to 10 % by weight of a lubricant. In a class of this embodiment the binding agent is polyvinylpyrrolidone or hydroxypropylcellulose, and the lubricant is magnesium stearate or sodium stearyl fumarate. In a subclass of this class, the binding agent is polyvinylpyrrolidone, and the lubricant is sodium stearyl fumarate. In another class the pharmaceutical compositions optionally contain about 0 to 3 % by weight of a surfactant and/or about 0 to 70 %.by weight of a diluent. In a subclass of this class, the surfactant is sodium lauryl sulfate and the diluent is microcrystalline cellulose.
In a second embodiment the pharmaceutical compositions of the present invention are prepared by wet granulation methods and comprise about 5 to 18 % by weight of a DPP-4 inhibitor as one of the two pharmaceutically active ingredients; about 65 to 77 % by weight of metformin hydrochloride as the second pharmaceutically active ingredient; about 4 to 9 % by weight of a binding agent; and about 1 to 2 % by weight of a lubricant. In a class of this embodiment the binding agent is polyvinylpyrrolidone or hydroxypropylcellulose, and the lubricant is magnesium stearate or sodium stearyl fumarate. . In a subclass of this class, the binding agent is polyvinylpyrrolidone. In another class the pharmaceutical compositions optionally contain about 0.5 to 1 % to by weight of a surfactant and/or about 5 to 15 % by weight of a diluent. In a subclass of this class, the surfactant is sodium lauryl sulfate and the diluent is microcrystalline cellulose.
In a further embodiment of the present invention, the pharmaceutical compositions as envisioned for commercial development are as follows: Tablets of 50 mg DPP-4 inhibitor/500 mg metformin HCl potency:
About 9 % by weight of the DPP-4 inhibitor; about 73 % by weight of metformin hydrochloride; about 7 % by weight of a binding agent; about 1 to 2 % by weight of a lubricant; and optionally about 10 % by weight of a diluent and/or about 0.5 % by weight of a surfactant. In a class of this embodiment the DPP-4 inhibitor is sitagliptin, vildagliptin, or saxagliptin; the binding agent is polyvinylpyrrolidone, the lubricant is magnesium stearate or sodium stearyl fumarate, the diluent is microcrystalline cellulose, and the surfactant is sodium lauryl sulfate. In a subclass of this class, the DPP-4 inhibitor is sitagliptin.
Tablets of 50 mg DPP-4 inhibitor/850 mg metformin HCl potency:
About 6 % by weight of the DPP-4 inhibitor; about 76 % by weight of metformin hydrochloride; about 7 % by weight of a binding agent; about 1 to 2 % by weight of a lubricant; and optionally about 10 % by weight of a diluent and/or about 0.5 % by weight of a surfactant. In a class of this embodiment the DPP-4 inhibitor is sitagliptin, vildagliptin, or saxagliptin; the binding agent is polyvinylpyrrolidone, the lubricant is magnesium stearate or sodium stearyl fumarate, the diluent is microcrystalline cellulose, and the surfactant is sodium lauryl sulfate. In a subclass the DPP-4 inhibitor is sitagliptin.
Tablets of 50 mg DPP-4 inhibitor/ 1000 mg metformin HCl potency:
About 5 % by weight of the DPP-4 inhibitor; about 77 % by weight of metformin hydrochloride; about 7 % by weight of a binding agent; about 1 to 2 % by weight of a lubricant; and . optionally about 10 % by weight of a diluent and/or about 0.5 % by weight of a surfactant. In a class of this embodiment the DPP-4 inhibitor is sitagliptin, vildagliptin, or saxagliptin; the binding agent is polyvinylpyrrolidone, the lubricant is magnesium stearate or sodium stearyl fumarate, the diluent is microcrystalline cellulose, and the surfactant is sodium lauryl sulfate. In a subclass the DPP-4 inhibitor is sitagliptin. .
Tablets of 100 mg DPP-4 inhibitor/500 mg metformin HCl potency:
About 17 % by weight of the DPP-4 inhibitor; about 65 % by weight of metformin hydrochloride; about 7 % by weight of a binding agent; about 1 to 2 % by weight of a lubricant; and optionally about 9 % by weight of a diluent and/or about 0.5 % by weight of a surfactant. In a class of this embodiment the DPP-4 inhibitor is sitagliptin, vildagiiptin, or saxagliptin; the binding agent is polyvinylpyrrolidone, the lubricant is magnesium stearate or sodium stearyl fumarate, the diluent is microcrystalline cellulose, and the surfactant is sodium lauryl sulfate. In a subclass the DPP-4 inhibitor is sitagliptin.
Tablets of 100 mg DPP-4 inhibitor/850 me metformin HCl potency:
About 11% by weight of the DPP-4 inhibitor; about 75 % by weight of metformin hydrochloride; about 7 % by weight of a binding agent; about 1 to 2 % by weight of a lubricant; and optionally about 4 % by weight of a diluent and/or about 0.5 % by weight of a surfactant. In a class of this embodiment the DPP-4 inhibitor is sitagliptin, vildagiiptin, or saxagliptin; the binding agent is polyvinylpyrrolidone, the lubricant is magnesium stearate or sodium stearyl fumarate, the diluent is microcrystalline cellulose, and the surfactant is sodium lauryl sulfate. In a subclass the DPP-4 inhibitor is sitagliptin.
Tablets of 100 mg DPP-4 inhibitor/1000 me metformin HCl potency:
About 10 % by weight of the DPP-4 inhibitor; about 77 % by weight of metformin hydrochloride; about 7 % by weight of a binding agent; about 1 to 2 % by weight of a lubricant; and optionally about 4 % by weight of a diluent and/or about 0.5 % by weight of a surfactant. In a class of this embodiment the DPP-4 inhibitor is sitagliptin, vildagiiptin, or saxagliptin; the binding agent is polyvinylpyrrolidone, the lubricant is magnesium stearate or sodium stearyl fumarate, the diluent is microcrystalline cellulose, and the surfactant is sodium lauryl sulfate. In a subclass the DPP-4 inhibitor is sitagliptin.
The pharmaceutical tablet compositions of the present invention may also contain one or more additional formulation ingredients selected from a wide variety of excipients known in the pharmaceutical formulation art. According to the desired properties of the pharmaceutical composition, any number of ingredients may be selected, alone or in combination, based upon their known uses in preparing tablet compositions. Such ingredients include, but are not limited to, diluents, compression aids, glidants, disintegrants, lubricants, flavors, flavor enhancers, sweeteners, and preservatives.
The term "tablet" as used herein is intended to encompass compressed pharmaceutical dosage formulations of all shapes and sizes, whether coated or uncoated. Substances which may be used for coating include hydroxypropylcellulose, hydroxypropylmethylcellulose, titanium dioxide, talc, sweeteners, colorants, and flavoring agents. In one embodiment the pharmaceutical compositions of the present invention are prepared by wet granulation (high shear and/or fluid bed). Granulation is a process in which binding agent is added either through the granulating solution or through addition to the granulating bowl to form granules. The steps involved in the wet granulation method comprise the following:
(1) the active pharmaceutical ingredients metformin hydrochloride and the DPP-4 inhibitor are added to the granulating bowl; (2) optional disintegrants are added to step 1 ;
(3) for high shear granulation, the binding agent (such as polyvinylpyrrolidone or hydroxypropylcellulose) is added dry to the granulating bowl and dry mixed for a short period followed by the addition of water with or without a surfactant (such as sodium lauryl sulfate). For fluid bed granulation, both active pharmaceutical ingredients are added to the granulator bowl and the granulating solution comprised of binding agent with or without surfactant in water is added upon fluidization;
(4) granules prepared by high shear granulation are tray-dried in an oven or dried in a fluid bed dryer. For granules prepared by fluid bed granulation, granules are dried in a fluid bed dryer;
(5) dried granules are resized in suitable mill; (6) optional diluents (such as microcrystalline cellulose and dibasic calcium phosphate dihydrate) are blended with dried granules in a suitable blender;
(7) lubricants or glidants (such as magnesium stearate and sodium stearyl fumarate) are added to the blend from step 6 in a suitable blender; .
(8) lubricated granule mixture from step 7 may be filled into bottles, sachets, or capsules or compressed into desired tablet image; . . . . , .
(9) and if desired, the resulting tablets may be film-coated.
The steps involved in the dry processing (direct compression or dry granulation) methods comprise:
(1) the active pharmaceutical ingredients metformin hydrochloride and the DPP-4 inhibitor are added to a suitable blender;
(2) optional disintegrants are added to step 1 ;
(3) optional binders and/or diluents are added to step 2;
(4) lubricants or glidants are added to step 3;
(5) mixture from step 4 may be filled into bottles, sachets, or capsules or compressed into desired tablet image, or processed through a roller compactor;
(6) if processed through a roller compaction, granules may be resized in a suitable mill, if necessary;
(7) optional diluents may be added to the resulting granules, in a suitable blender to improve compaction properties; . .
(8) optional lubricants or glidants are added to the blend from step 7; (9) lubricated granule mixture from step 8 may be filled into bottles, sachets, or capsules or compressed into desired tablet image;
(10) and if desired, the resulting tablets from step 5 or step 9 may be film-coated. The present invention also provides methods for treating Type 2 diabetes by orally administering to a host in need of such treatment a therapeutically effective amount of one of the fixed- dose combination pharmaceutical compositions of the present invention. In one embodiment the host in need of such treatment is a human. In another embodiment the pharmaceutical composition is in the dosage form of a tablet. The pharmaceutical compositions comprising the fixed-dose combination may be administered once-daily (QD), twice-daily (BID), or thrice-daily (TID).
The following examples further describe and demonstrate embodiments within the scope of the present invention. The examples are given solely for the purpose of illustration and are not intended to be construed as limitations of the present invention as many variations thereof are possible without departing from the spirit and scope of the invention.
EXAMPLE l
Fixed-dose combination of 50 milligrams sitaeliptin and 500 milligrams metformin hvdrochloride/per tablet — wet granulation
Figure imgf000011_0001
* Equivalent to 50 mg of sitagliptin free base anhydrate. ** Removed during processing.
Method. of Manufacture:
Sitagliptin phosphate monohydrate and metformin hydrochloride were loaded into a high shear granulator or a fluid bed granulator. In the case of high shear granulation, purified water containing sodium lauryl sulfate was added to the APIs, in addition to the polyvinylpyrrolidone binding agent over a period of 3-5 minutes. The wetted mass was either tray dried at 40 0C or dried in a fluid-bed dryer at an inlet temperature of 45-600C for 3-6 minutes. In the case of fluid bed granulation, purified water containing polyvinylpyrrolidone and sodium lauryl sulfate was added to APIs over a period of 30- 60 minutes. The wetted mass was dried in a fluid-bed dryer at an inlet temperature of 45-60 0C. The dried material was then milled using a co-mill to achieve fine granules. After milling, microcrystalline cellulose was added to the granules and blended in a twin shell-blender for 200 revolutions. The lubricant (sodium stearyl fumarate) was then added and blended an additional 100 revolutions. The lubricated mixture was compressed using a rotary tablet press to provide a 689 mg uncoated tablet. The tablets were optionally coated with Opadry® II suspension (polyvinyl alcohol, polyethylene glycol, titanium dioxide, and talc, with or without colorants) to an approximate 2.5% weight gain to provide a 706 mg coated tablet.
EXAMPLE 2
Fixed-dose combination of 50 milligrams sitagliptin and 850 milligrams metformin hydrochloride/per tablet — wet granulation
Figure imgf000012_0001
* Equivalent to 50 mg of sitagliptin free base anhydrate. ** Removed during processing.
Method of Manufacture:
Tablets were prepared by wet-granulation using essentially the procedure of Example 1 to provide a 1117 mg uncoated tablet. The tablets were optionally coated with 27.9 mg of a standard Opadry II film-coat formula to provide a 1145 mg coated tablet.
EXAMPLE 3
Fixed-dose combination of 50 milligrams sitagliptin and 1000 milligrams metformin hvdrochloride/per tablet — wet granulation
Figure imgf000012_0002
Figure imgf000013_0001
* Equivalent to 50 mg of sitagliptin free base anhydrate. ** Removed during processing.
Method of Manufacture;
Tablets were prepared by wet-granulation using essentially the procedure of Example 1 to provide a 1300 mg uncoated tablet. The tablets were optionally coated with an Opadry® π suspension (polyvinyl alcohol, polyethylene glycol, titanium dioxide, and talc, with or without colorants) to an approximate 2.5% weight gain to provide a 1333 mg coated tablet.
EXAMPLE 4
Fixed-dose combination of 50 milligrams sitagliptin and 500 milligrams metformin hydrochloride/per tablet — wet granulation
Figure imgf000013_0002
* Equivalent to 50 mg of sitagliptin free base anhydrate. ** Removed during processing.
Method of Manufacture:
Sitagliptin phosphate monohydrate and metformin hydrochloride were loaded into a high shear granulator or a fluid bed granulator. In the case of high shear granulation, purified water was added to the APIs, in addition to the polyvinylpyrrolidone binding agent over a period of 3-5 minutes. The wetted mass was either tray dried at 400C or dried in a fluid-bed dryer at an inlet temperature of 45- 60 0C for 3-6 minutes. In the case of fluid bed granulation, purified water containing polyvinylpyrrolidone was added to APIs over a period of 30-60 minutes. The wetted mass was dried in a fluid-bed dryer at an inlet temperature of 45-60 0C. The dried material was then milled using a co-mill to achieve fine granules. After milling, microcrystalline cellulose was added to the granules and blended in a twin shell-blender for 200 revolutions. The lubricant (magnesium stearate) was then added and blended an additional 100 revolutions. The lubricated mixture was compressed using a rotary tablet press to provide a 689 mg uncoated tablet. The tablet was then optionally film-coated with an Opadry® II suspension (polyvinyl alcohol, polyethylene glycol, titanium dioxide, and talc, with or without colorants) to an approximate 2.5% weight gain to provide a 706 mg coated tablet.
EXAMPLE 5
Fixed-dose combination of 50 milligrams sitagliptin and 1000 milligrams metformin hvdrochloride/per tablet — wet granulation
Figure imgf000014_0001
* Equivalent to 50 mg of sitagliptin free base anhydrate. ** Removed during processing.
Method of Manufacture:
Sitagliptin phosphate monohydrate and metformin hydrochloride were loaded into a high shear granulator or a fluid bed granulator. In the case of high shear granulation, purified water containing sodium lauryl sulfate was added to the APIs, in addition to the polyvinylpyrrolidone binding agent over a period of 3-5 minutes. The wetted mass was either tray dried at 40 0C or dried in a fluid-bed dryer at an inlet temperature of 45-60 "C for 3-6 minutes. In the case of fluid bed granulation, purified water containing polyvinylpyrrolidone and sodium lauryl sulfate was added to APIs over a period of 30- 60 minutes. The wetted mass was dried in a fluid-bed dryer at an inlet temperature of 45-60 0C. The dried material was then milled using a co-mill to achieve fine granules. After milling, microcrystalline cellulose was added to the granules and blended in a twin shell-blender for 200 revolutions. The lubricant (magnesium stearate) was then added and blended an additional 100 revolutions. The lubricated mixture was compressed using a rotary tablet press to provide a 1300 mg uncoated tablet. The tablet was then optionally film-coated with an Opadry® II suspension (polyvinyl alcohol, polyethylene glycol, titanium dioxide, and talc, with or without colorants) to an approximate 2.5% weight gain to provide a 1333 mg coated tablet.
EXAMPLE 6
Fixed-dose combination of 100 milligrams sitagliptin and 1000 milligrams metformin hvdrochloride/per tablet — wet granulation
Figure imgf000015_0001
* Equivalent to 100 mg of sitagliptin free base anhydrate. ** Removed during processing.
Method of Manufacture: Tablets were prepared by fluid-bed granulation using essentially the procedure of
Example 1 to provide a 1300 mg uncoated tablet.
EXAMPLE 7
Fixed-dose combination of 100 milligrams sitagliptin and 500 milligrams metformin hvdrochloride/per tablet — wet granulation
Figure imgf000015_0002
* Equivalent to 50 mg of sitagliptin free base anhydrate. ** Removed during processing. Method of Manufacture:
Tablets were prepared by fluid-bed granulation using essentially the procedure of Example 1 to provide a 768 mg uncoated tablet.

Claims

WHAT IS CLAIMED IS:
1. A pharmaceutical composition comprising:
(a) about 3 to 20 % by weight of a dipeptidyl peptidase-4 (DPP-4) inhibitor or a pharmaceutically acceptable salt thereof;
(b) about 25 to 94 % by weight of metformin hydrochloride;
(c) about 0.1 to 10 % by weight of a lubricant; and
(d) about 0 to 35 % by weight of a binding agent.
2. The pharmaceutical composition of Claim 1 additionally comprising one or more excipients selected from the group consisting of (a) diluent; (b) a disintegrant; (c) a surfactant; (d) a wetting agent; and (e) an anti-oxidant.
3. The pharmaceutical composition of Claim 1 comprising: (a) about 5 to 18 % by weight of a DPP-4 inhibitor or a pharmaceutically acceptable salt thereof;
(b) about 65 to 77 % by weight of metformin hydrochloride;
(c) about 1 to 2 % by weight of a lubricant; and
(d) about 4 to.9 % by weight of a binding agent.
4. The pharmaceutical composition of Claim 3 additionally comprising about 0.5 to
1 % by weight of a surfactant and/or about 5 to 15 % by weight of a diluent.
5. The pharmaceutical composition of Claim 3 wherein said lubricant is magnesium stearate or sodium stearyl fumarate, and the binding agent is polyvinylpyrrolidone.
6. The pharmaceutical composition of Claim 3 comprising:
(a) about 9 % by weight of a DPP-4 inhibitor or a pharmaceutically acceptable salt thereof;
(b) about 73 % by weight of metformin hydrochloride;
(c) about 1 to 2 % by weight of a lubricant; and (d) about 7 % by weight of a binding agent.
7. The pharmaceutical composition of Claim 6 additionally comprising about 0,5 % by weight of a surfactant and/or about 10 % by weight of a diluent.
8. The pharmaceutical composition of Claim 3 comprising
(a) about 5 % by weight of a DPP-4 inhibitor or a pharmaceutically acceptable salt thereof;
(b) about 77 % by weight of metformin hydrochloride; (c) about 1 to 2 % by weight of a lubricant; and
(d) about 7 % by weight of a binding agent.
9. The pharmaceutical composition of Claim 8 additionally comprising about 0.5 % by weight of a surfactant and/or about 10 % by weight of a diluent.
10. The pharmaceutical composition of Claim 3 wherein said DPP-4 inhibitor is selected from the group consisting of sitagliptin, vildagliptm, and saxagliptin, and pharmaceutically acceptable salts of each thereof.
11. The pharmaceutical composition of Claim 10 wherein said DPP-4 inhibitor is sitagliptin or the dihydrogenphosphate salt thereof.
12. A pharmaceutical composition comprising: (a) a DPP-4 inhibitor present in a unit dosage strength of 25 to 200 milligrams;
(b) metformin hydrochloride present in a unit dosage strength of 250, 500, 625, 750, 850, or 1000 milligrams;
(c) about 1 to 2 % by weight of a lubricant;
(d) about 7 % by weight of a binding agent; and optionally (e) about 10 % by weight of a diluent; and optionally
(f) about 0.5 % by weight of a surfactant. :
13. The pharmaceutical composition of Claim 12 wherein said DPP-4 inhibitor is sitagliptin, said lubricant is sodium stearyl fumarate, said binding agent is polyvinylpyrrolidone, said optional diluent is microcrystalline cellulose, and said optional surfactant is sodium lauryl sulfate.
14. The pharmaceutical composition of Claim 12 wherein said DPP-4 inhibitor is present in a unit dosage strength of 25, 50, 75, 100, 150, or 200 milligrams, and said metformin hydrochloride is present in a unit dosage strength of 500, 850, or 1000 milligrams. . . .' ■ ' " '
15. The pharmaceutical composition of Claim 14 wherein said DPP-4 inhibitor is present in a unit dosage strength of 50 milligrams, and said metformin hydrochloride is present in a unit dosage strength of 500, 850, or 1000 milligrams.
16. The pharmaceutical composition of Claim 15 wherein said DPP-4 inhibitor is sitagliptin.
17. The pharmaceutical composition of Claim 16 wherein said sitagliptin is present in a unit dosage strength of 50 milligrams, and said metformin hydrochloride is present in a unit dosage strength of 500 or 1000 milligrams.
18. The pharmaceutical composition of Claim 1 or 14 wherein said composition is in the dosage form of a tablet.
19. A method of treating Type 2 diabetes in a human in need thereof comprising orally administering to said human a pharmaceutical composition of Claim 1 or 14.
20. The pharmaceutical composition of Claim 1 further comprising one or more agents selected from the group consisting of flavoring agents, colorants, and sweeteners.
21. The pharmaceutical composition of Claim 1 or 3 prepared by wet granulation methods.
22. The pharmaceutical composition of Claim 12 wherein said DPP-4 inhibitor is ■ vildagliptin or saxagliptin or a pharmaceutically acceptable salt of each thereof.
PCT/US2006/047380 2005-12-16 2006-12-12 Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin WO2007078726A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US12/085,722 US8414921B2 (en) 2005-12-16 2006-12-12 Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
EP06839329A EP1962827A4 (en) 2005-12-16 2006-12-12 Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
CN2006800471037A CN101365432B (en) 2005-12-16 2006-12-12 Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
JP2008545737A JP5165582B2 (en) 2005-12-16 2006-12-12 Pharmaceutical composition comprising a combination of a dipeptidyl peptidase-4 inhibitor and metformin
AU2006333151A AU2006333151B2 (en) 2005-12-16 2006-12-12 Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
CA002633167A CA2633167A1 (en) 2005-12-16 2006-12-12 Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75095405P 2005-12-16 2005-12-16
US60/750,954 2005-12-16

Publications (2)

Publication Number Publication Date
WO2007078726A2 true WO2007078726A2 (en) 2007-07-12
WO2007078726A3 WO2007078726A3 (en) 2008-06-12

Family

ID=38228726

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/047380 WO2007078726A2 (en) 2005-12-16 2006-12-12 Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin

Country Status (7)

Country Link
US (1) US8414921B2 (en)
EP (1) EP1962827A4 (en)
JP (2) JP5165582B2 (en)
CN (1) CN101365432B (en)
AU (1) AU2006333151B2 (en)
CA (1) CA2633167A1 (en)
WO (1) WO2007078726A2 (en)

Cited By (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009121945A2 (en) * 2008-04-03 2009-10-08 Boehringer Ingelheim International Gmbh New formulations, tablets comprising such formulations, their use and process for their preparation
WO2010044637A2 (en) 2008-10-17 2010-04-22 동아제약 주식회사 Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-iv, and other antidiabetic or antiobesity agents as active ingredients
US7820815B2 (en) 2004-11-05 2010-10-26 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines
EP2295083A1 (en) 2009-09-15 2011-03-16 Ratiopharm GmbH Pharmaceutical composition comprising active agents metformin and sitagliptin or vildagliptin
EP2402342A1 (en) * 2010-03-08 2012-01-04 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition for treatment of 2 type dabetes
US8106060B2 (en) 2005-07-30 2012-01-31 Boehringer Ingelheim International Gmbh 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
US8119648B2 (en) 2002-08-21 2012-02-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US8232281B2 (en) 2006-05-04 2012-07-31 Boehringer Ingelheim International Gmbh Uses of DPP-IV inhibitors
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US8551524B2 (en) 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
US8551957B2 (en) 2007-08-16 2013-10-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
US8691832B2 (en) 2010-12-06 2014-04-08 Merck Sharp & Dohme Corp. Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors
US8697868B2 (en) 2004-02-18 2014-04-15 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
WO2014101986A1 (en) 2012-12-27 2014-07-03 Zentiva Sağlik Ürünleri San. Ve Tic. A.Ş. Dry granulation process for producing tablet compositions of metformin and compositions thereof
EP2769712A1 (en) * 2013-02-21 2014-08-27 Siegfried International AG Pharmaceutical formulation comprising DPP-IV inhibitor agglomerates and DPP-IV inhibitor particles
US8846695B2 (en) 2009-01-07 2014-09-30 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
US8853212B2 (en) 2010-02-22 2014-10-07 Merck Sharp & Dohme Corp Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
US8853156B2 (en) 2008-08-06 2014-10-07 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US8895603B2 (en) 2011-06-29 2014-11-25 Merck Sharp & Dohme Corp. Crystalline forms of a dipeptidyl peptidase-IV inhibitor
TWI462925B (en) * 2010-09-27 2014-12-01 Jiangsu Hengrui Medicine Co Pharmaceutical composition for the treatment of type 2 diabetes
US8900638B2 (en) 2007-07-19 2014-12-02 Takeda Pharmaceutical Company Limited Solid preparation comprising alogliptin and metformin hydrochloride
US8980929B2 (en) 2010-05-21 2015-03-17 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US9051329B2 (en) 2011-07-05 2015-06-09 Merck Sharp & Dohme Corp. Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors
US9073930B2 (en) 2012-02-17 2015-07-07 Merck Sharp & Dohme Dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
WO2015114152A1 (en) 2014-02-03 2015-08-06 Galenicum Health S.L. Stable pharmaceutical compositions containing sitagliptin in the form of immediate release tablets
US9149478B2 (en) 2010-06-24 2015-10-06 Boehringer Ingelheim International Gmbh Diabetes therapy
US9156848B2 (en) 2012-07-23 2015-10-13 Merck Sharp & Dohme Corp. Treating diabetes with dipeptidyl peptidase-IV inhibitors
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
US9266888B2 (en) 2006-05-04 2016-02-23 Boehringer Ingelheim International Gmbh Polymorphs
US9315508B2 (en) 2012-07-23 2016-04-19 Merck Sharp & Dohme Corp. Treating diabetes with dipeptidyl peptidase-IV inhibitors
KR20160111237A (en) 2015-03-16 2016-09-26 한미약품 주식회사 An oral composite formulation containing metformin and sitagliptin
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US9486526B2 (en) 2008-08-06 2016-11-08 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US9526730B2 (en) 2012-05-14 2016-12-27 Boehringer Ingelheim International Gmbh Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
AU2014262269B2 (en) * 2008-04-03 2017-02-02 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
CN106580962A (en) * 2016-12-30 2017-04-26 江苏晶立信医药科技有限公司 Compound metformin and vildagliptin tablet and preparation method thereof
US9713618B2 (en) 2012-05-24 2017-07-25 Boehringer Ingelheim International Gmbh Method for modifying food intake and regulating food preference with a DPP-4 inhibitor
US9783531B2 (en) 2013-12-20 2017-10-10 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9862725B2 (en) 2014-07-21 2018-01-09 Merck Sharp & Dohme Corp. Process for preparing chiral dipeptidyl peptidase-IV inhibitors
US20180185291A1 (en) 2011-03-07 2018-07-05 Boehringer Ingelheim International Gmbh Pharmaceutical compositions
EP2498758B1 (en) 2009-11-13 2018-07-25 AstraZeneca AB Bilayer tablet formulations
EP2498759B1 (en) 2009-11-13 2018-08-01 AstraZeneca AB Immediate release tablet formulations
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
US10406172B2 (en) 2009-02-13 2019-09-10 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP2459531B1 (en) * 2009-07-31 2019-09-11 KRKA, D.D., Novo Mesto Granulate comprising vildagliptin and process for its preparation
WO2019240699A2 (en) 2017-12-28 2019-12-19 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tablet formulations comprising metformin and sitagliptin processed with hot-melt extrusion
US10646446B2 (en) 2010-10-14 2020-05-12 Novartis Ag Pharmaceutical compositions containing a DGAT1 inhibitor
WO2020098904A1 (en) 2018-11-12 2020-05-22 Pharmaceutical Oriented Services Ltd Dosage form containing metformin and a dipeptidyl peptidase iv inhibitor
WO2021076066A1 (en) * 2019-10-14 2021-04-22 Santa Farma İlaç Sanayi̇ A.Ş. Oral formulations comprising sitagliptin hci monohydrate with improved pharmaceutical characteristics
EP3811930A1 (en) * 2019-10-24 2021-04-28 Authenda Pharmaceuticals AG Oral gliptin compositions and method for preparation thereof
US11033552B2 (en) 2006-05-04 2021-06-15 Boehringer Ingelheim International Gmbh DPP IV inhibitor formulations
EP3698801A4 (en) * 2017-10-20 2021-07-21 Novmetapharma Co., Ltd. Pharmaceutical composition for preventing or treating diabetes, containing zinc salt, cyclo-hispro and antidiabetic drug as active ingredients
WO2022070209A1 (en) * 2020-09-29 2022-04-07 Dr. Reddy's Laboratories Limited Biphasic release fixed dose combination formulations
WO2022228735A1 (en) * 2021-04-27 2022-11-03 Pharmathen S.A. Pharmaceutical composition comprising a combination of sitagliptin and metformin and method of preparation thereof
EP2482812B1 (en) * 2009-10-02 2023-01-11 Boehringer Ingelheim International GmbH Pharmaceutical compositions comprising bi-1356 and metformin
US11911388B2 (en) 2008-10-16 2024-02-27 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
WO2024086263A1 (en) 2022-10-21 2024-04-25 Merck Sharp & Dohme Llc Compositions of a dipeptidyl peptidase-iv inhibitor and an antioxidant

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2668662A1 (en) * 2006-11-14 2008-05-22 Merck & Co., Inc. Tricyclic heteroaromatic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
EP2124901B1 (en) * 2007-02-01 2017-07-19 Takeda Pharmaceutical Company Limited Tablet preparation without causing a tableting trouble
CA2638240C (en) * 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
CN101849944A (en) * 2009-03-31 2010-10-06 江苏恒瑞医药股份有限公司 Medicinal composition for treating type 2 diabetes
CN101899048B (en) * 2009-05-27 2013-04-17 上海恒瑞医药有限公司 Salt of (R)-7-[3-amino-4-(2,4,5-trifluoro-phenyl)-butyryl]-3-trifluoromethyl-5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine-1- carboxylic acid methyl ester
CN101904840B (en) * 2009-06-08 2012-02-08 江苏恒瑞医药股份有限公司 Medicinal composition for treating type 2 diabetes of mammal including human
CN101919851B (en) * 2009-06-09 2012-02-08 江苏恒瑞医药股份有限公司 Medicinal composition for treating type 2 diabetes of mammalian and human
AU2012277373A1 (en) * 2011-06-29 2014-01-30 Sun Pharmaceutical Industries Limited Solid dispersions of sitagliptin and processes for their preparation
WO2013110085A1 (en) * 2012-01-20 2013-07-25 Handa Pharmaceuticals, Llc Oral dosage forms for delivering metformin and sitagliptin
TWI469785B (en) * 2012-04-25 2015-01-21 Inovobiologic Inc Dietary fiber compositions for the treatment of metabolic disease
WO2013171766A2 (en) * 2012-05-15 2013-11-21 Hetero Research Foundation Saxagliptin solid dispersion
WO2014170770A1 (en) 2013-03-28 2014-10-23 Wockhardt Limited Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof
WO2014174469A1 (en) 2013-04-25 2014-10-30 Ranbaxy Laboratories Limited Pharmaceutical compositions comprising a combination of sitagliptin and metformin
WO2014184742A1 (en) 2013-05-13 2014-11-20 Ranbaxy Laboratories Limited Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent
CN104161752B (en) * 2013-05-16 2018-09-07 江苏豪森药业集团有限公司 A kind of vildagliptin composition
JP5922310B2 (en) * 2013-07-25 2016-05-24 株式会社三和化学研究所 Pharmaceutical formulation
CN103463090A (en) * 2013-09-11 2013-12-25 深圳翰宇药业股份有限公司 Preparation method of sitagliptin metformin hydrochloride compound preparation
CN103735544B (en) * 2014-02-14 2015-08-19 南京华威医药科技开发有限公司 A kind of preparation technology of vildagliptin/metformin hydrochloride compound preparation
WO2016016770A1 (en) 2014-07-26 2016-02-04 Wockhardt Limited A novel modified release pharmaceutical composition of sitagliptin or pharmaceutically acceptable salt thereof
KR101526825B1 (en) * 2014-12-23 2015-06-08 주식회사 한독 Pharmaceutical Compositions for The Treatment of Diabetes
CN106580960A (en) * 2015-10-19 2017-04-26 南京优科制药有限公司 Preparation method of vildagliptin and metformin hydrochloride compound preparation
CN106074553B (en) * 2016-06-13 2019-02-22 杭州华东医药集团新药研究院有限公司 Pharmaceutical composition containing Xi Gelieting and melbine
US11096890B2 (en) 2017-09-29 2021-08-24 Merck Sharp & Dohme Corp. Chewable dosage forms containing sitagliptin and metformin
JP7166754B2 (en) * 2017-11-22 2022-11-08 沢井製薬株式会社 Formulations containing dasatinib anhydrate
KR102647472B1 (en) * 2018-07-31 2024-03-14 한미약품 주식회사 Solid composite formulation for oral administration comprising dipeptidyl peptidase-4 inhibitor and metformine, and a process for the preparation thereof
EP4188352A1 (en) * 2020-07-31 2023-06-07 KRKA, d.d., Novo mesto Pharmaceutical formulation of metformin having low content of dimethylamine
CN113143929B (en) * 2021-04-15 2023-04-07 浙江诺得药业有限公司 Preparation method of sitagliptin compound preparation
CA3215858A1 (en) 2021-04-27 2022-11-03 Zhenhuan ZHENG Combination of bitter receptor agonist and gut-signaling compound
CN114042051A (en) * 2021-11-19 2022-02-15 平光制药股份有限公司 Pharmaceutical composition containing sitagliptin and metformin and preparation method thereof
CN116327769A (en) * 2021-12-16 2023-06-27 重庆圣华曦药业股份有限公司 Pharmaceutical composition containing sitagliptin phosphate and metformin hydrochloride and preparation method thereof
CN115245495B (en) * 2022-09-21 2022-12-23 北京惠之衡生物科技有限公司 Sitagliptin and metformin tablet and preparation method thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1052994A2 (en) 1998-02-02 2000-11-22 Trustees Of Tufts College Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
DE19823831A1 (en) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim New pharmaceutical use of isoleucyl thiazolidide and its salts
JP2003520759A (en) * 1999-08-31 2003-07-08 アンドルックス ファーマスーティカルズ インコーポレーテッド Sustained-release tablet with unit core
DE60124861T2 (en) * 2000-01-21 2007-05-10 Novartis Ag COMPOSITIONS CONTAINING DIPEPTIDYLPEPTIDASE-IV INHIBITORS AND ANTIDIABETICA
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US7078397B2 (en) 2000-06-19 2006-07-18 Smithkline Beecham Corporation Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
AU2002357767C1 (en) * 2001-11-26 2009-03-19 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes
KR20100137023A (en) * 2002-09-20 2010-12-29 안드렉스 랩스 엘엘씨 Pharmaceutical tablet
US20050051922A1 (en) * 2002-09-20 2005-03-10 Avinash Nangia Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
US20060046979A1 (en) 2002-09-24 2006-03-02 Foster Carolyn A Organic compounds
JPWO2004028524A1 (en) * 2002-09-26 2006-01-19 エーザイ株式会社 Concomitant medication
DK1556362T3 (en) 2002-10-18 2008-06-09 Merck & Co Inc Heterocyclic beta-aminodipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
EP1578414A4 (en) * 2002-12-04 2007-10-24 Merck & Co Inc Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CA2508947A1 (en) * 2002-12-20 2004-07-15 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US20040229848A1 (en) * 2003-05-05 2004-11-18 Hans-Ulrich Demuth Glutaminyl based DP IV-inhibitors
FR2858556B1 (en) * 2003-08-06 2006-03-10 Galenix Innovations DISPERSIBLE AND / OR ORODISPERSIBLE SOLID PHARMACEUTICAL COMPOSITION, NOT PELLETIZED, CONTAINING AT LEAST THE METFORMIN ACTIVE INGREDIENT, AND PROCESS FOR PREPARING THE SAME
ATE534404T1 (en) * 2003-10-03 2011-12-15 Takeda Pharmaceutical DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OF DIABETES PATIENTS WITH SECONDARY FAILURE DUE TO SULFONYL UREAS
US20050163850A1 (en) * 2003-10-31 2005-07-28 Wong Patrick S. Administration of levodopa and carbidopa
CA2545311C (en) * 2003-11-12 2012-01-03 Phenomix Corporation Heterocyclic boronic acid compounds
BRPI0507972A (en) 2004-02-23 2007-07-24 Tufts College compound, pharmaceutical composition, use of a compound, method for inhibiting the proteolytic activity of a postproline cleavage enzyme and packaged pharmaceutical composition
CN101090885A (en) * 2004-02-23 2007-12-19 塔夫茨大学信托人 Lactams as comformationally constrained peptidomimetic inhibitors
EP2801354B1 (en) * 2004-10-08 2017-02-08 Forward Pharma A/S Controlled release pharmaceutical compositions comprising a fumaric acid ester
WO2006047248A1 (en) 2004-10-25 2006-05-04 Novartis Ag Combination of dpp-iv inhibitor, ppar antidiabetic and metformin
GT200600008A (en) 2005-01-18 2006-08-09 FORMULATION OF DIRECT COMPRESSION AND PROCESS
CN101277949A (en) * 2005-04-22 2008-10-01 阿兰托斯制药控股公司 Dipeptidyl peptidase-iv inhibitors
US20060270722A1 (en) * 2005-05-31 2006-11-30 Thornberry Nancy A Combination of a dipeptidyl peptidase-IV inhibitor and a dual PPAR agonist for the treatment of diabetes and obesity
MY152185A (en) 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
BRPI0614610A2 (en) * 2005-08-04 2011-04-05 Novartis Ag compounds
JOP20180109A1 (en) * 2005-09-29 2019-01-30 Novartis Ag New Formulation
US20080064701A1 (en) 2007-04-24 2008-03-13 Ramesh Sesha Anti-diabetic combinations
US20070172525A1 (en) 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1962827A4 *

Cited By (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8664232B2 (en) 2002-08-21 2014-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US10023574B2 (en) 2002-08-21 2018-07-17 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US8178541B2 (en) 2002-08-21 2012-05-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US8119648B2 (en) 2002-08-21 2012-02-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US10202383B2 (en) 2002-08-21 2019-02-12 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US9108964B2 (en) 2002-08-21 2015-08-18 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US9321791B2 (en) 2002-08-21 2016-04-26 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US9556175B2 (en) 2002-08-21 2017-01-31 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions
US8697868B2 (en) 2004-02-18 2014-04-15 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US8883805B2 (en) 2004-11-05 2014-11-11 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US7820815B2 (en) 2004-11-05 2010-10-26 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines
US9751855B2 (en) 2004-11-05 2017-09-05 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US9499546B2 (en) 2004-11-05 2016-11-22 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US8541450B2 (en) 2004-11-05 2013-09-24 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1yl)-xanthines
US8637530B2 (en) 2005-07-30 2014-01-28 Boehringer Ingelheim International Gmbh 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
US8106060B2 (en) 2005-07-30 2012-01-31 Boehringer Ingelheim International Gmbh 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
US9173859B2 (en) 2006-05-04 2015-11-03 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US8673927B2 (en) 2006-05-04 2014-03-18 Boehringer Ingelheim International Gmbh Uses of DPP-IV inhibitors
US9266888B2 (en) 2006-05-04 2016-02-23 Boehringer Ingelheim International Gmbh Polymorphs
US8232281B2 (en) 2006-05-04 2012-07-31 Boehringer Ingelheim International Gmbh Uses of DPP-IV inhibitors
US10301313B2 (en) 2006-05-04 2019-05-28 Boehringer Ingelheim International Gmbh Polymorphs
US9493462B2 (en) 2006-05-04 2016-11-15 Boehringer Ingelheim International Gmbh Polymorphs
US11084819B2 (en) 2006-05-04 2021-08-10 Boehringer Ingelheim International Gmbh Polymorphs
US11033552B2 (en) 2006-05-04 2021-06-15 Boehringer Ingelheim International Gmbh DPP IV inhibitor formulations
US10080754B2 (en) 2006-05-04 2018-09-25 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US11919903B2 (en) 2006-05-04 2024-03-05 Boehringer Ingelheim International Gmbh Polymorphs
US9815837B2 (en) 2006-05-04 2017-11-14 Boehringer Ingelheim International Gmbh Polymorphs
US11291668B2 (en) 2006-05-04 2022-04-05 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US8900638B2 (en) 2007-07-19 2014-12-02 Takeda Pharmaceutical Company Limited Solid preparation comprising alogliptin and metformin hydrochloride
US8551957B2 (en) 2007-08-16 2013-10-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
US8551524B2 (en) 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
WO2009121945A3 (en) * 2008-04-03 2009-12-03 Boehringer Ingelheim International Gmbh Dpp-iv inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US10022379B2 (en) 2008-04-03 2018-07-17 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
KR101775942B1 (en) 2008-04-03 2017-09-07 베링거 인겔하임 인터내셔날 게엠베하 DPP-IV Inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US10973827B2 (en) 2008-04-03 2021-04-13 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
CN106215190A (en) * 2008-04-03 2016-12-14 勃林格殷格翰国际有限公司 The DPP IV inhibitor combined with other antidiabetic drug, the tablet comprising this type of preparation, and its Use and preparation method
KR101611314B1 (en) 2008-04-03 2016-04-11 베링거 인겔하임 인터내셔날 게엠베하 DPP-IV Inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
EA029395B1 (en) * 2008-04-03 2018-03-30 Бёрингер Ингельхайм Интернациональ Гмбх Pharmaceutical composition comprising a dpp-4 inhibitor and metformin, process for the preparation thereof and solid dosage form comprising said composition
WO2009121945A2 (en) * 2008-04-03 2009-10-08 Boehringer Ingelheim International Gmbh New formulations, tablets comprising such formulations, their use and process for their preparation
EP4144374A1 (en) * 2008-04-03 2023-03-08 Boehringer Ingelheim International GmbH Dpp-iv inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
JP2013237707A (en) * 2008-04-03 2013-11-28 Boehringer Ingelheim Internatl Gmbh New formulation, tablet comprising the formulation, the use and process for the preparation
EA038435B1 (en) * 2008-04-03 2021-08-27 Бёрингер Ингельхайм Интернациональ Гмбх Use of a pharmaceutical composition in the form of a film-coated tablet in treating type 2 diabetes mellitus
EP3453403A1 (en) * 2008-04-03 2019-03-13 Boehringer Ingelheim International GmbH Dpp-iv inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
JP2011516456A (en) * 2008-04-03 2011-05-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel formulations, tablets containing the formulations, their use and methods for their preparation
AU2014262269B2 (en) * 2008-04-03 2017-02-02 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US9415016B2 (en) 2008-04-03 2016-08-16 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US9155705B2 (en) 2008-04-03 2015-10-13 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
AU2009232043B2 (en) * 2008-04-03 2014-09-25 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US8853156B2 (en) 2008-08-06 2014-10-07 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US9486526B2 (en) 2008-08-06 2016-11-08 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US10034877B2 (en) 2008-08-06 2018-07-31 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US11911388B2 (en) 2008-10-16 2024-02-27 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
EP2351567A2 (en) * 2008-10-17 2011-08-03 Dong-A Pharmaceutical Co., Ltd. Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-iv, and other antidiabetic or antiobesity agents as active ingredients
JP2012505876A (en) * 2008-10-17 2012-03-08 ドン・ア・ファーム・カンパニー・リミテッド Pharmaceutical composition for preventing and treating diabetes or obesity comprising a compound that inhibits the activity of dipeptidyl peptidase-IV and a different anti-diabetic or anti-obesity drug as active ingredients
WO2010044637A2 (en) 2008-10-17 2010-04-22 동아제약 주식회사 Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-iv, and other antidiabetic or antiobesity agents as active ingredients
US8440669B2 (en) 2008-10-17 2013-05-14 Dong-A Pharmaceutical Co. Ltd. Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-IV, and other antidiabetic or antiobesity agents as active ingredients
EP2351567A4 (en) * 2008-10-17 2013-12-04 Dong A Pharm Co Ltd Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-iv, and other antidiabetic or antiobesity agents as active ingredients
US9212183B2 (en) 2008-12-23 2015-12-15 Boehringer Ingelheim International Gmbh Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
US8846695B2 (en) 2009-01-07 2014-09-30 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
US10406172B2 (en) 2009-02-13 2019-09-10 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP2459531B1 (en) * 2009-07-31 2019-09-11 KRKA, D.D., Novo Mesto Granulate comprising vildagliptin and process for its preparation
WO2011032912A1 (en) 2009-09-15 2011-03-24 Ratiopharm Gmbh Pharmaceutical composition having the active substances metformin and sitagliptin or vildaliptin
EA021634B1 (en) * 2009-09-15 2015-07-30 Рациофарм Гмбх Pharmaceutical composition having the active substances metformin and sitagliptin or vildagliptin
EP2295083A1 (en) 2009-09-15 2011-03-16 Ratiopharm GmbH Pharmaceutical composition comprising active agents metformin and sitagliptin or vildagliptin
EP2482812B1 (en) * 2009-10-02 2023-01-11 Boehringer Ingelheim International GmbH Pharmaceutical compositions comprising bi-1356 and metformin
EP2498759B1 (en) 2009-11-13 2018-08-01 AstraZeneca AB Immediate release tablet formulations
EP2498758B1 (en) 2009-11-13 2018-07-25 AstraZeneca AB Bilayer tablet formulations
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US10092571B2 (en) 2009-11-27 2018-10-09 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US8853212B2 (en) 2010-02-22 2014-10-07 Merck Sharp & Dohme Corp Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
KR20130006567A (en) * 2010-03-08 2013-01-17 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Pharmaceutical composition for treatment of 2 type dabetes
JP2013521223A (en) * 2010-03-08 2013-06-10 ジエンス ヘンルイ メデイシンカンパニー リミテッド Pharmaceutical composition for the treatment of type 2 diabetes
EP2402342A4 (en) * 2010-03-08 2012-09-19 Jiangsu Hengrui Medicine Co Pharmaceutical composition for treatment of 2 type diabetes
KR101686265B1 (en) 2010-03-08 2016-12-13 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Pharmaceutical composition for treatment of 2 type diabetes
EP2402342A1 (en) * 2010-03-08 2012-01-04 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition for treatment of 2 type dabetes
US10004747B2 (en) 2010-05-05 2018-06-26 Boehringer Ingelheim International Gmbh Combination therapy
US9603851B2 (en) 2010-05-05 2017-03-28 Boehringer Ingelheim International Gmbh Combination therapy
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
US8980929B2 (en) 2010-05-21 2015-03-17 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
US9149478B2 (en) 2010-06-24 2015-10-06 Boehringer Ingelheim International Gmbh Diabetes therapy
TWI462925B (en) * 2010-09-27 2014-12-01 Jiangsu Hengrui Medicine Co Pharmaceutical composition for the treatment of type 2 diabetes
US10646446B2 (en) 2010-10-14 2020-05-12 Novartis Ag Pharmaceutical compositions containing a DGAT1 inhibitor
US11304907B2 (en) 2010-10-14 2022-04-19 Novartis Ag Pharmaceutical compositions containing a DGAT1 inhibitor
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US11911387B2 (en) 2010-11-15 2024-02-27 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US8691832B2 (en) 2010-12-06 2014-04-08 Merck Sharp & Dohme Corp. Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors
US20180185291A1 (en) 2011-03-07 2018-07-05 Boehringer Ingelheim International Gmbh Pharmaceutical compositions
US11564886B2 (en) 2011-03-07 2023-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical compositions
US10596120B2 (en) 2011-03-07 2020-03-24 Boehringer Ingelheim International Gmbh Pharmaceutical compositions
US8895603B2 (en) 2011-06-29 2014-11-25 Merck Sharp & Dohme Corp. Crystalline forms of a dipeptidyl peptidase-IV inhibitor
US9181262B2 (en) 2011-06-29 2015-11-10 Merck Sharp & Dohme Corp Crystalline forms of a dipeptidyl peptidase-IV inhibitors
US9187488B2 (en) 2011-06-29 2015-11-17 Merck Sharp & Dohme Corp Process for preparing chiral dipeptidyl peptidase-IV inhibitors
US9527855B2 (en) 2011-06-29 2016-12-27 Merck Sharp & Dohme Corp. Process for preparing chiral dipeptidyl peptidase-IV inhibitors
US9051329B2 (en) 2011-07-05 2015-06-09 Merck Sharp & Dohme Corp. Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors
US9199998B2 (en) 2011-07-15 2015-12-01 Boehringer Ingelheim Internatioal Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US8962636B2 (en) 2011-07-15 2015-02-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9073930B2 (en) 2012-02-17 2015-07-07 Merck Sharp & Dohme Dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9526730B2 (en) 2012-05-14 2016-12-27 Boehringer Ingelheim International Gmbh Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US10195203B2 (en) 2012-05-14 2019-02-05 Boehringr Ingelheim International GmbH Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US9713618B2 (en) 2012-05-24 2017-07-25 Boehringer Ingelheim International Gmbh Method for modifying food intake and regulating food preference with a DPP-4 inhibitor
US9156848B2 (en) 2012-07-23 2015-10-13 Merck Sharp & Dohme Corp. Treating diabetes with dipeptidyl peptidase-IV inhibitors
US9315508B2 (en) 2012-07-23 2016-04-19 Merck Sharp & Dohme Corp. Treating diabetes with dipeptidyl peptidase-IV inhibitors
RU2647421C2 (en) * 2012-12-27 2018-03-15 Зентива Саглык Урунлеры Сан. Ве Тыдж. А.Ш. Dry granulation process for producing tablet compositions of metformin and compositions thereof
WO2014101986A1 (en) 2012-12-27 2014-07-03 Zentiva Sağlik Ürünleri San. Ve Tic. A.Ş. Dry granulation process for producing tablet compositions of metformin and compositions thereof
WO2014128209A1 (en) * 2013-02-21 2014-08-28 Siegfried International Ag Pharmaceutical formulation comprising dpp-iv inhibitor agglomerates
EP2769712A1 (en) * 2013-02-21 2014-08-27 Siegfried International AG Pharmaceutical formulation comprising DPP-IV inhibitor agglomerates and DPP-IV inhibitor particles
US9783531B2 (en) 2013-12-20 2017-10-10 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015114152A1 (en) 2014-02-03 2015-08-06 Galenicum Health S.L. Stable pharmaceutical compositions containing sitagliptin in the form of immediate release tablets
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
US9862725B2 (en) 2014-07-21 2018-01-09 Merck Sharp & Dohme Corp. Process for preparing chiral dipeptidyl peptidase-IV inhibitors
US10053466B2 (en) 2014-07-21 2018-08-21 Merck Sharp & Dohme Corp. Process for preparing chiral dipeptidyl peptidase-IV inhibitors
KR20160111237A (en) 2015-03-16 2016-09-26 한미약품 주식회사 An oral composite formulation containing metformin and sitagliptin
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
CN106580962B (en) * 2016-12-30 2020-11-10 江苏晶立信医药科技有限公司 Metformin and vildagliptin compound tablet and preparation method thereof
CN106580962A (en) * 2016-12-30 2017-04-26 江苏晶立信医药科技有限公司 Compound metformin and vildagliptin tablet and preparation method thereof
EP3698801A4 (en) * 2017-10-20 2021-07-21 Novmetapharma Co., Ltd. Pharmaceutical composition for preventing or treating diabetes, containing zinc salt, cyclo-hispro and antidiabetic drug as active ingredients
US11607441B2 (en) 2017-10-20 2023-03-21 Novmetapharma Co., Ltd. Pharmaceutical composition for preventing or treating diabetes, containing zinc salt, cyclo-hispro and antidiabetic drug as active ingredients
WO2019240699A2 (en) 2017-12-28 2019-12-19 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tablet formulations comprising metformin and sitagliptin processed with hot-melt extrusion
WO2020098904A1 (en) 2018-11-12 2020-05-22 Pharmaceutical Oriented Services Ltd Dosage form containing metformin and a dipeptidyl peptidase iv inhibitor
WO2021076066A1 (en) * 2019-10-14 2021-04-22 Santa Farma İlaç Sanayi̇ A.Ş. Oral formulations comprising sitagliptin hci monohydrate with improved pharmaceutical characteristics
EP3811930A1 (en) * 2019-10-24 2021-04-28 Authenda Pharmaceuticals AG Oral gliptin compositions and method for preparation thereof
WO2021078964A1 (en) 2019-10-24 2021-04-29 Authenda Pharmaceuticals Ag Oral gliptin compositions and method for preparation thereof
US11944621B2 (en) 2019-10-24 2024-04-02 Authenda Pharmaceuticals Ag Oral gliptin compositions and method for preparation thereof
WO2022070209A1 (en) * 2020-09-29 2022-04-07 Dr. Reddy's Laboratories Limited Biphasic release fixed dose combination formulations
WO2022228735A1 (en) * 2021-04-27 2022-11-03 Pharmathen S.A. Pharmaceutical composition comprising a combination of sitagliptin and metformin and method of preparation thereof
WO2024086263A1 (en) 2022-10-21 2024-04-25 Merck Sharp & Dohme Llc Compositions of a dipeptidyl peptidase-iv inhibitor and an antioxidant

Also Published As

Publication number Publication date
AU2006333151B2 (en) 2010-03-04
JP2013047260A (en) 2013-03-07
CN101365432A (en) 2009-02-11
EP1962827A2 (en) 2008-09-03
EP1962827A4 (en) 2011-02-16
US20090105265A1 (en) 2009-04-23
JP2009519934A (en) 2009-05-21
US8414921B2 (en) 2013-04-09
JP5165582B2 (en) 2013-03-21
WO2007078726A3 (en) 2008-06-12
CN101365432B (en) 2011-06-22
AU2006333151A1 (en) 2007-07-12
JP5779566B2 (en) 2015-09-16
CA2633167A1 (en) 2007-07-12

Similar Documents

Publication Publication Date Title
US8414921B2 (en) Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
US20120059011A1 (en) Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
US20100330177A1 (en) Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
US20120201885A1 (en) Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
JP2011513408A (en) Combination pharmaceutical composition of metformin and dipeptidyl peptidase-IV inhibitor
WO2012173877A1 (en) Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with simvastatin
EP2402342B1 (en) Pharmaceutical composition for treatment of 2 type diabetes
US8476272B2 (en) Pharmaceutical composition for treatment of type 2 diabetes
TWI494313B (en) Pharmaceutical composition for the treatment of type 2 diabetes in mammals including human beings
TWI462925B (en) Pharmaceutical composition for the treatment of type 2 diabetes
WO2011009360A1 (en) Pharmaceutical composition for treatment of type 2 diabetes in mammals including human beings
TWI484955B (en) Pharmaceutical composition for the treatment of type 2 diabetes in mammals including human beings

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680047103.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2008545737

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12085722

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2006333151

Country of ref document: AU

Ref document number: 2710/CHENP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2633167

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006839329

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006333151

Country of ref document: AU

Date of ref document: 20061212

Kind code of ref document: A